BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250624
DTEND;VALUE=DATE:20250627
DTSTAMP:20260515T035145
CREATED:20250409T112357Z
LAST-MODIFIED:20250409T112504Z
UID:40904-1750723200-1750982399@www.pharmajournalist.com
SUMMARY:8th International Neoantigen Summit
DESCRIPTION:2024 saw a wealth of clinical progression with Nouscom\, CureVac\, Transgene and other pioneering companies paving the way for neoantigen based vaccines and therapies to become tolerable\, durable medicines to effectively treat cancer.\nReady to unite the global neoantigen community\, the 8th International Neoantigen Summit 2025 returns to address key challenges in the discovery\, translation and clinical development of safe and cost-effective neoantigen therapies and vaccines to attract investors and ultimately improve the health of patients. \nJoin neoantigen leaders from the likes of AstraZeneca\, Geneos Therapeutics\, Evaxion Biotech and many more at this end-to-end meeting\, focusing on the development of durable\, neoantigen cancer vaccines and cell therapies. With the potential to deliver safe\, efficacious personalized or off-the-shelf therapeutic options to patients\, this is your chance to collaborate and accelerate the translation of neoantigen-based therapies from discovery to clinical success. \nTo know more visit: https://ter.li/zdfjes
URL:https://www.pharmajournalist.com/event/8th-international-neoantigen-summit/
LOCATION:Steigenberger Airport Hotel Amsterdam\, Stationsplein Zuid-West 951\, 1117 CE Schiphol\, Netherlands\, 1117 CE\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250624
DTEND;VALUE=DATE:20250627
DTSTAMP:20260515T035145
CREATED:20250304T114230Z
LAST-MODIFIED:20250304T114358Z
UID:40629-1750723200-1750982399@www.pharmajournalist.com
SUMMARY:5th Medical Device Software Development Summit
DESCRIPTION:The 5th Medical Device Software Development Summit is your must-attend opportunity to gain actionable strategies\, real-world case studies\, and expert insights to confidently develop\, secure\, and regulate cutting-edge medical device software – without compromise. \nDedicated to navigating the complexities of US and global regulations\, addressing cybersecurity vulnerabilities\, and managing legacy device updates\, this summit unites 120+ industry leaders – from medical device giants to innovative start-ups – to explore actionable strategies\, share best practices\, and collaborate on solutions for ensuring the continuous compliance and security of cutting-edge software in a rapidly evolving market. \nWhat Will you Gain: \n\nStay Ahead of Regulatory Changes: Gain insights from Biogen\, Werfen\, and Olympus on the latest FDA\, EU MDR\, and global compliance updates\, ensuring your products meet evolving standards.\nSecure & Accelerate Your Software: Learn how Medtronic\, RETINA-AI\, and Abbott are addressing cybersecurity risks\, enhancing software validation\, and leveraging AI-powered innovation to streamline development processes.\nUnlock AI for Safer\, Faster Development: Discover how HeartSciences\, Kheiron\, and Globe Biomedical are utilizing AI to expedite software testing\, improve validation\, and bolster cybersecurity\, leading to safer and more efficient medical device development.\n\n\nDon’t miss this summit – join us in Boston this June to stay ahead\, gain crucial insights\, benchmark and fuse knowledge from software\, QA\, RA and product teams to align innovation in software with evolving processes\, cybersecurity\, and global regulatory frameworks in new and legacy devices. \nView the full Event Guide here: https://ter.li/cziksw
URL:https://www.pharmajournalist.com/event/5th-medical-device-software-development-summit/
LOCATION:The Royal Sonesta Boston\, 40 Edwin H Land Blvd\, Cambridge\, MA\, 02142\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250624
DTEND;VALUE=DATE:20250627
DTSTAMP:20260515T035145
CREATED:20250225T182337Z
LAST-MODIFIED:20250228T133908Z
UID:40588-1750723200-1750982399@www.pharmajournalist.com
SUMMARY:CPHI & PMEC China 2025
DESCRIPTION:CPHI & PMEC China is Asia’s premier pharmaceutical event for sourcing\, networking\, learning and innovation with over 20 years’ experience of bringing together Chinese and global pharma professionals. \n \nCPHI & PMEC China 2025 will cover more than 230\,000 square meters of exhibition area\, attract over 90\,000 global attendees and 3\,500 exhibitors\, and hold more than 100 conferences during the exhibition. \nCPHI & PMEC China 2025 showcases a wide range of pharmaceutical products and services\, including: active pharmaceutical ingredients\, Intermediates & fine chemicals\, excipients\, finished dosage formulation\, biopharmaceuticals\, natural extracts\, CMO & CRO\, machinery & equipment\, packaging & drug delivery\, laboratory equipment\, cleanroom & pollution control etc. \nClick here to register now.
URL:https://www.pharmajournalist.com/event/cphi-pmec-china-2025/
LOCATION:Shanghai New International Expo Centre\, Shanghai\, China
ORGANIZER;CN="Shanghai Sinoexpo Informa Markets International Exhibition Co.%2C Ltd.":MAILTO:CPHImarketing@imsinioexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250623
DTEND;VALUE=DATE:20250626
DTSTAMP:20260515T035145
CREATED:20250327T135543Z
LAST-MODIFIED:20250328T115442Z
UID:40760-1750636800-1750895999@www.pharmajournalist.com
SUMMARY:10th Annual Microbiome Movement Summit
DESCRIPTION:Returning for its 10th anniversary\, the Microbiome Movement Summit remains the premier global gathering for microbiome drug developers\, uniting experts across discovery\, preclinical\, translational\, regulatory\, and commercial sectors to drive innovation in the microbiome space. \nConnect with over 140+ experts from diverse fields within microbiome R&D\, including representatives from Pulmobiotics\, Seres Therapeutics\, BiomeBank\, and PharmaBiome. Engage in dynamic discussions\, forge valuable partnerships\, and gain actionable insights that will drive your microbiome research and development forward. This summit is your chance to be at the forefront of microbiome innovation and to collaborate with the brightest minds in the industry. \nWhat’s New for 2025? \n– Hear Brand New Insights from Industry Trailblazers: Gain key updates from leaders at Ferring Pharmaceuticals\, Siolta Therapeutics\, MaaT Pharma\, and Corundum Systems Biology as they discuss clinical advancements and commercial strategies shaping the future of microbiome therapeutics. \n– 18 New Organizations Taking the Stage: Discover the latest contributions from emerging companies such as Azitra\, Kanvas Bio\, Alveolus Bio\, Microviable Therapeutics\, Unilever\, Mikrobiomik\, Jona\, Nestle Health Science\, and more\, with each presenting their innovative approaches and breakthroughs in microbiome research. \n– Unlock the Next Wave of Microbiome-Based Drug Development: Explore groundbreaking synthetic biology innovations\, AI-driven strain engineering\, and advanced bioinformatics tools that are accelerating the discovery and optimization of microbiome-based therapies. \n– Advance Clinical Translation & Regulatory Success: Learn how companies are overcoming challenges in CMC\, large-scale manufacturing\, and regulatory approval\, with insights on recent FDA approvals\, IND-enabling studies\, and global market access strategies. \nGet your copy of the latest brochure here: https://ter.li/cdfr4c
URL:https://www.pharmajournalist.com/event/10th-annual-microbiome-movement-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T035145
CREATED:20250305T141309Z
LAST-MODIFIED:20250305T142300Z
UID:40667-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:4th World ADC Asia Summit
DESCRIPTION:Linking the East to the West in the ADC World | 在ADC世界连接东西方 | ADC 세계에서 동서 연결하기ADCの世界で東西をつなぐ \nIn 2025\, Asia will continue leading ADC innovation\, with growth in dual-payload ADCs\, bispecific ADCs\, and novel linker-payload technologies. Staying informed through clinical updates\, connecting with new companies\, and building collaborations will be key to seizing emerging opportunities. \nThe 4th World ADC Asia Summit (June 10-12\, 2025\, | Incheon\, South Korea)\, part of the globally recognized World ADC series\, serves as the premier platform for showcasing the latest advancements in R&D\, clinical validation\, and commercialization. \nThis industry-leading event unites Asia’s top innovators with global expertise to drive ADC success across the region. \nWhat’s New in 2025? \n Three dynamic tracks covering discovery\, preclinical\, clinical\, and CMC\nExclusive seminar days on ADC fundamentals & Bispecific ADCs – Whether you’re just starting out or a seasoned expert\, the program offers something for professionals at every level\n Unparalleled networking with leading experts and organizations \nA Global Speaker Lineup \nWith 20+ new companies joining our esteemed panel from China\, Japan\, Korea\, Taiwan\, Singapore\, the US\, and Europe—featuring industry leaders such as AstraZeneca\, AbbVie\, HoneyBear Biosciences\, Chiome Bioscience\, and more—this is a must-attend event for anyone in the ADC field. \nLearn more here: https://ter.li/iimxna
URL:https://www.pharmajournalist.com/event/4th-world-adc-asia-summit/
LOCATION:Grand Hyatt Incheon\, 208 Yeongjonghaeannam-ro 321beon-gil\, Jung-gu\, Incheon\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T035145
CREATED:20250409T111953Z
LAST-MODIFIED:20250409T111953Z
UID:40897-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:Vendor Management & Outsourcing for Clinical Trials Summit
DESCRIPTION:Vendor management processes are crucial for ensuring compliance\, quality\, and timely delivery at every stage\, serving as the backbone of successful clinical trials. Acknowledging the transformative impact\, the industry is prioritizing the optimization of these intricate processes\, making significant investments to enhance key functions\, improve performance\, and maintain a competitive edge. Despite this professionals managing ancillary lab vendors and CROs lack a dedicated forum to address their unique challenges\, until now… \nIntroducing the Vendor Management & Outsourcing for Clinical Trials Summit\, built with the industry to the needs of vendor management\, outsourcing and clinical operations professionals. \nTo know more visit: https://ter.li/d1jemt
URL:https://www.pharmajournalist.com/event/vendor-management-outsourcing-for-clinical-trials-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T035145
CREATED:20250206T124225Z
LAST-MODIFIED:20250220T125930Z
UID:40428-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:2nd Annual IMPACCT Real World Evidence Summit Europe
DESCRIPTION:This year’s IMPACCT Real World Evidence Europe conference is the only case-study led industry forum providing actionable insights into numerous challenges such as optimizing evidence generation plans in early stages\, enhancing collaboration between industry and public research to advance RWE\, consolidating cross-functional collaboration to improve effectiveness of RWE studies\, and exploring actionable study designs that empower patients to elevate RWE utility… \nAs regulators and payers increasingly elevate the importance of RWE in submission requirements and with an explosion of datasets opening up in parallel with advancing AI\, deep learning\, and large language models transforming big data analysis\, it has never been more critical to keep up with the matrix of country-specific regulatory nuances and industry case studies in optimizing integrated evidence plans\, bullet-proofing data quality\, and navigating vendor selection. \nThe 2nd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE and Evidence Generation to consolidate\, innovate and apply RWE across the drug development lifecycle\, from external control arms to reimbursement. \nWith a tight focus on leveraging AI for both efficiency gains and big data analysis\, the latest on DARWIN and using RWE to support regulatory decision-making\, and creating a robust integrated evidence strategy\, join 60+ industry pioneers from AstraZeneca\, Pfizer\, Novartis\, Sanofi and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice\, ensuring resilience and success in a dynamic landscape as a successful business partner. \nJoin us\, our speakers\, attendees and sponsors to explore strategies\, learn efficient data deployment and automation\, learn best practices for sharing real-time data and insights cross-functionally\, inform your development processes\, address biases and study product life cycle management to bridge the gap from clinical trials to real-world evidence. \nWith over 50 industry pioneers we have the force to form a comprehensive evidence plan\, break free from silos\, and bridge the gap between clinical research and practice. Get in the room with Presidents\, VPs\, Directors\, Head\, Managers and Lead Scientists all on the same mission as you. \nThis is your one opportunity to liaise with like-minded\, driven and curious individuals about industry innovation. \nTo know more visit: https://ter.li/e8cs7v
URL:https://www.pharmajournalist.com/event/2nd-annual-impacct-real-world-evidence-summit-europe/
LOCATION:Steigenberger Airport Hotel\, Amsterdam\, Stationsplein Zuid-West 951\, Schiphol\, 1117 CE\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T035145
CREATED:20250108T111946Z
LAST-MODIFIED:20250108T112021Z
UID:40293-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:7th Annual Allogeneic Cell Therapies Summit
DESCRIPTION:With the autoimmune wave breathing financial life back into the allogeneic space\, and a growing number of oncology pipelines entering the clinic\, the allogeneic community are eagerly anticipating what lies ahead! \nMaking now the ideal time to attend the 7th Annual Allogeneic Cell Therapies Summit (June 10-12 | Boston\, MA)\, your flagship forum uniting the top allogeneic developers including Atara Bio\, Adicet Bio\, Senti Bio\, Glycostem and more. \nWhat Will 2025 Offer? \n\nGround-breaking Clinical Readouts: Dive into the latest results from CAR-T therapies with Atara Bio and Adicet Bio.\nSolid Tumor Breakthroughs: Hear from Senti Bio\, NKILT Therapeutics\, and Synaptimmune on how allogeneic therapies are targeting the tumor microenvironment to unlock entirely new indications.\nManufacturing at Scale: Learn how Tevogen and Cell BioEngines are navigating the complexities of scalable\, high-quality manufacturing to make these therapies commercially viable.\nBeyond Oncology: Broaden your scope by discovering how Biosyngen and Adicet Bio are leveraging allogeneic platforms to address autoimmune disorders.\n\nAs regulatory frameworks evolve to accommodate these revolutionary therapies and investment creeps back into allogeneic development\, staying informed is no longer optional. Get involved today to be part of the conversations solving today’s challenges and shaping tomorrow’s breakthroughs. \nFind out more: https://ter.li/o21go2
URL:https://www.pharmajournalist.com/event/7th-annual-allogeneic-cell-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250609
DTEND;VALUE=DATE:20250612
DTSTAMP:20260515T035145
CREATED:20250304T113738Z
LAST-MODIFIED:20250304T113738Z
UID:40624-1749427200-1749686399@www.pharmajournalist.com
SUMMARY:Innovation in Psychosis Therapeutics Summit
DESCRIPTION:The Innovation in Psychosis Therapeutics Summit is the premier industry forum dedicated to advancing next-generation approaches for psychosis treatment. As 2025 marks a pivotal year for psychosis drug development—with a surge in clinical advancements and key collaborations gaining momentum—this inaugural event unites the brightest minds in biotech and pharma to overcome critical challenges in drug discovery and development. \n \nDesigned specifically for R&D leaders\, this summit is uniquely positioned to tackle the biggest hurdles in the field\, including translational validity\, patient heterogeneity\, placebo effect\, and trial scalability. By bringing together 60+ key stakeholders from discovery\, preclinical\, translational\, and clinical development\, this meeting provides a platform to collaborate\, exchange insights\, and shape the future of psychosis treatment. \nWith the growing urgency to address the significant unmet need in psychosis and the limitations of current atypical antipsychotics\, the time is now to drive innovation forward. Join the conversation as industry pioneers build on Cobenfy’s breakthrough success and explore cutting-edge strategies to develop more effective\, better-tolerated therapeutics across the psychosis spectrum. \nDon’t miss this brand-new opportunity to connect with thought leaders\, gain critical insights\, and be at the forefront of transforming psychosis R&D. \nTo know more visit: https://ter.li/9yj2vx
URL:https://www.pharmajournalist.com/event/innovation-in-psychosis-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250603
DTEND;VALUE=DATE:20250606
DTSTAMP:20260515T035145
CREATED:20250228T121911Z
LAST-MODIFIED:20250228T121911Z
UID:40598-1748908800-1749167999@www.pharmajournalist.com
SUMMARY:2nd Structure-Based Drug Design Summit
DESCRIPTION:With tightening budgets and increasing pressure to de-risk R&D\, pharma and biotech are shifting their focus toward smarter\, more efficient drug design. Companies are investing more in enabling technologies—from computational modeling and AI-driven predictions to structural biology techniques like Cryo-EM\, NMR\, and X-ray crystallography—to improve rational drug design and enhance decision-making early in discovery. \nWhile AI-powered structure prediction is transforming the landscape—recognized by the 2024 Nobel Prize for Google DeepMind’s AlphaFold2— its true impact depends on experimental validation. The ability to integrate computational insights with high-resolution structural data is now essential for unlocking complex targets and accelerating drug discovery. \nCryo-EM continues to push the limits of resolution for complex targets and Cryo-ET is emerging as a potential game-changer for biopharma – the future of structure-based drug design is here. \nThe 2nd Structure-Based Drug Design Summit is the only industry-dedicated meeting bringing together the latest advancements in integrative structural biology and computational tools to accelerate early drug discovery. Across three days of expert-led discussions and case studies\, you’ll gain insights into how leading scientists are leveraging Cryo-EM\, NMR\, X-ray crystallography\, and AI to solve high-value targets and drive rational drug design across small molecules\, peptides\, biologics\, and vaccines. \nWith coverage of design of TPDs\, molecular glues\, vaccines\, antibodies\, and mRNA\, GPCRs and membrane protein targeting therapeutics plus much more! \nThe field is evolving—don’t get left behind. Expand your network and join 80+ structural biologists\, medicinal chemists\, protein engineers\, and computational chemists in Boston this June and be part of the next wave of structure-based drug design innovation.
URL:https://www.pharmajournalist.com/event/2nd-structure-based-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250528
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T035145
CREATED:20250219T115152Z
LAST-MODIFIED:20250219T115152Z
UID:40525-1748390400-1748563199@www.pharmajournalist.com
SUMMARY:3rd Gene Therapy Potency Assay Summit
DESCRIPTION:Accelerating the Route to Commercialization with Robust Potency Assay Development \nFollowing a challenging year in the gene therapy field\, the 3rd Gene Therapy Potency Assay Summit returns at a crucial time when drug developers increasingly recognize that a robust potency assay is fundamental to both clinical success and commercial viability. As regulatory expectations continue to evolve\, it has never been more important to develop assays that are accurate\, reproducible\, and aligned with regulatory standards. \nWhile many industry meetings touch on potency in a broad or non-technical manner\, this summit stands apart as the only event fully dedicated to the complexities of potency assay development. With an emphasis on deep technical discussions\, attendees will gain unparalleled insights into phase-appropriate assay development\, methodology advancements\, reducing lot-to-lot variability\, and meeting evolving regulatory expectations. By bringing together a specialized community of Analytical Development\, Quality Control\, and Regulatory experts\, this meeting offers a unique platform to discuss challenges\, share strategies\, and explore innovative solutions. \nOne of the key highlights of this year’s agenda is the session “Navigating Regulatory Requirements for Gene Therapy Potency Assays”\, presented by Melody Dai\, Vice President\, Head of Regulatory Affairs & CMC at Novasenta. This session\, taking place at 9:00 AM on Day 1\, will provide an in-depth exploration of regulatory strategies for potency assays\, covering both early and ongoing regulatory engagement. Attendees will learn how to build effective relationships with regulatory agencies\, navigate evolving requirements\, and prepare for critical regulatory meetings and submissions. By leveraging insights from experts with hands-on experience in clinical-stage gene therapy products\, this session will offer practical guidance that extends beyond theoretical discussions. \nWith a carefully curated agenda and contributions from industry leaders\, the 3rd Gene Therapy Potency Assay Summit provides an essential opportunity to advance potency assay strategies\, enhance regulatory preparedness\, and accelerate the path to commercialization. Whether you are refining your assay methodologies\, tackling regulatory complexities\, or preparing for the next phase of development\, this event will equip you with the expertise and connections needed to drive success in gene therapy. \nFind Out More Now!
URL:https://www.pharmajournalist.com/event/3rd-gene-therapy-potency-assay-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250528
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T035145
CREATED:20250217T143826Z
LAST-MODIFIED:20250217T143826Z
UID:40519-1748390400-1748563199@www.pharmajournalist.com
SUMMARY:4th Circular & Self-Amplifying RNA Therapeutics Summit
DESCRIPTION:Join the 4th Circular & Self-Amplifying RNA Therapeutics Summit! \nUnleashing the Next Generation of RNAs for Widespread Therapeutic Applications \nWith CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine\, the field of next generation RNAs celebrates the potential of circular and self-amplifying RNAs to provide improved stability\, durability\, longevity and efficacy for treating a wide array of diseases. \nThis May\, the 4th Circular & Self-Amplifying RNA Therapeutics Summit (previously known as ‘Next Generation RNA Therapeutics Summit) is landing back in Boston\, as the unique opportunity to unite with leading stakeholders in the next generation RNA field\, including the likes of Sail Biomedicines\, Merck\, Novo Nordisk\, Replicate Bioscience and more. This is your one-stop shop to hear the latest approaches and applications of circular and self-amplifying RNA therapeutics and vaccines and gain actionable insights for fast-tracking your RNA programs toward the clinic. \nJoin 80+ RNA experts navigating through challenges such as RNA design\, delivery\, purity\, and manufacturing to accelerate high-quality and scalable next-generation RNA therapeutics and vaccines towards approval and the patients in need. \nTo know more visit: https://ter.li/lemzh2
URL:https://www.pharmajournalist.com/event/4th-circular-self-amplifying-rna-therapeutics-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T035145
CREATED:20250416T103747Z
LAST-MODIFIED:20250416T103747Z
UID:40951-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:2nd Cell & Gene Therapy Pricing & Reimbursement Summit
DESCRIPTION:Current limitations across pricing\, coverage\, and payment frameworks are lasering out and hindering global access to many approved cell and gene therapies (CGTs). The Cell & Gene Therapy Pricing & Reimbursement Summit is here to change that. \nReturning for its 2nd edition\, this unique summit will share real-world case studies of success and setback in ensuring patients can access CGTs to spearhead reform in this thorny landscape. \nIndustry-led discussions will center on innovative payment models being developed and applied\, new stop-loss and reinsurance programs\, and how leading companies are ensuring coverage and uptake of their commercialized therapies. You’ll also leave with actionable learnings from recent CMS policy changes\, including the Access Model\, Medicaid Drug Rebate Program Final Rule\, and proposed increases to inpatient CAR-T reimbursement rates. \nJoin leading biopharma\, government agencies\, commercial payers\, academics\, and market access-specialist service providers – to align on the current market access strategy and policy challenges hindering widespread adoption of these ground-breaking therapies\, enhance your payer coverage and improve patient access. \nTo know more visit: https://ter.li/0g5eq9
URL:https://www.pharmajournalist.com/event/2nd-cell-gene-therapy-pricing-reimbursement-summit/
LOCATION:Marriott Washington Capitol Hill\, 175 L Street NE\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T035145
CREATED:20250307T113641Z
LAST-MODIFIED:20250307T113641Z
UID:40683-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:3rd Retinal Imaging Biomarkers & Endpoints Summit
DESCRIPTION:The 3rd Retinal Imaging Biomarkers & Endpoints Summit will bring together leading experts spanning medical directors\, researchers\, clinical\, and imaging scientists from more than 30 organizations spearheading ophthalmic development with deep learning systems and sophisticated AI imaging technologies. It’s here they will explore the latest advancements in retinal imaging\, biomarkers\, and endpoints for ophthalmic drug development. \nThis highly anticipated meeting will delve into the evolving landscape of retinal diseases\, offering in-depth discussions on innovative imaging techniques\, biomarker discovery\, and the critical role of endpoints in clinical trials. Attendees will have the opportunity to engage with top-tier scientists\, researchers\, and industry leaders who will be presenting cutting-edge research\, techniques\, and case studies\, providing you with hyper-relevant insights to accelerate your ophthalmic development. \nTopics will cover a range of retinal conditions\, including dry and wet AMD\, GA\, GR\, and DME\, focusing on the identification and validation of biomarkers that are vital for diagnosis\, prognosis\, and treatment response assessment. This meeting is the perfect bridge for those developing and using novel technologies to ensure the efficacious development of endpoints for regulatory approval. \nAttendees will benefit from interactive workshops\, panel discussions\, and case studies\, providing practical insights into the real-world challenges and opportunities in retinal disease research. Plus\, with 8+ hours of dedicated networking sessions designed to ensure attendees get to meet everyone in the room\, it’s a fantastic opportunity to build valuable connections and strengthen collaboration which will aid in fostering partnerships that will drive the future of retinal imaging and treatment outcomes. \nAnd with sessions being delivered by Alexion\, Opus Genetics\, Inflammx\, Bausch + Lomb\, REGENXBIO\, and many more you won’t want to miss this! \nWhether you’re a researcher\, drug developer\, clinician or solution provider\, the 3rd Retinal Imaging Biomarkers & Endpoints Summit promises to be a pivotal point in the calendar for those involved in the development of therapies for retinal diseases. \nJoin us to be at the forefront of this rapidly advancing field and contribute to the next wave of innovations in retinal health… \nView the event guide for more information: https://ter.li/hcmzr0 \nSecure your pass: https://ter.li/tq8jmz
URL:https://www.pharmajournalist.com/event/3rd-retinal-imaging-biomarkers-endpoints-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250520
DTEND;VALUE=DATE:20250523
DTSTAMP:20260515T035145
CREATED:20250422T121846Z
LAST-MODIFIED:20250422T122446Z
UID:40956-1747699200-1747958399@www.pharmajournalist.com
SUMMARY:6th Gene Therapy Analytical Development Summit Europe
DESCRIPTION:The 6th Gene Therapy Analytical Development Summit Europe is the leading platform for advancing gene therapy analytics\, from IND/IMPD filings to clinical trials and regulatory approvals. As the field moves toward late-stage development\, gain industry-focused insights tailored for Europe. \nJoin 24+ experts to tackle characterisation\, stability\, contamination risks\, and comparability across vectors and diseases. Network with biotech\, pharma\, MHRA\, and British Pharmacopoeia to share solutions and shape the future of gene therapy. \nDon’t miss the chance to explore analytical precision\, QC strategy\, and the delivery of safe\, effective therapies! \nTo know more visit: https://ter.li/w8deua
URL:https://www.pharmajournalist.com/event/6th-gene-therapy-analytical-development-summit-europe/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250520
DTEND;VALUE=DATE:20250523
DTSTAMP:20260515T035145
CREATED:20250225T113954Z
LAST-MODIFIED:20250225T113954Z
UID:40583-1747699200-1747958399@www.pharmajournalist.com
SUMMARY:4th GPCRs-Targeted Drug Discovery Summit
DESCRIPTION:The 4th GPCR-Targeted Drug Discovery Summit: Transforming the Discovery of Novel GPCR-Targeted Therapies. \nWith positive clinical read outs by Tectonic Therapeutics and recent funding rounds for Confo Therapeutics & Septerna\, the potential for novel GPCR drug classes to treat a plethora of diseases grows. Now more than ever\, there is a need for the community to come together to share scientific advancements and collaboration opportunities across the full spectrum of GPCR drugs\, from small molecules to therapeutic proteins and antibodies. \nThe 4th GPCRs-Targeted Drug Discovery Summit is returning to Boston to showcase the hottest targets of interest\, mechanism of action of new GPCR ligands\, cutting-edge computational tools to identify high-potential candidates\, and effective translational strategies to drive forward discovery & development pipelines to patients in need.\n\nFind out everything you need to know about the Summit here: https://ter.li/2c54a7
URL:https://www.pharmajournalist.com/event/4th-gpcrs-targeted-drug-discovery-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250519
DTEND;VALUE=DATE:20250521
DTSTAMP:20260515T035145
CREATED:20250402T111945Z
LAST-MODIFIED:20250402T111945Z
UID:40815-1747612800-1747785599@www.pharmajournalist.com
SUMMARY:TPD & Induced Proximity Pharma Partnering Summit
DESCRIPTION:From molecular glue discovery to the development of degrader-antibody conjugates\, pharma is transforming through strategic transactions and by leveraging protein degradation technologies to expand target discovery and drug previously ‘undruggable’ targets. \nThis provides biotech with the opportunity to understand pharma’s targets of interest and the options for increased specificity and selectivity compared to traditional molecules. \nJoin the TPD & Induced Proximity Pharma Partnering Summit to accelerate partnership interest in your protein degradation pipeline or platform\, by hearing first-hand: \n\nWhat: What are pharma’s targets of interest\, and what data is sparking or prohibiting deal-making across TPD?\nWho: Who is the right person at each pharma\, specifically for induced proximity assets?\nHow: How are pharma analyzing data for a research collaboration versus a licensing deal?\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:https://www.pharmajournalist.com/event/tpd-induced-proximity-pharma-partnering-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250513
DTEND;VALUE=DATE:20250516
DTSTAMP:20260515T035145
CREATED:20250214T120932Z
LAST-MODIFIED:20250214T120932Z
UID:40492-1747094400-1747353599@www.pharmajournalist.com
SUMMARY:3rd Precision Medicine in Inflammatory Bowel Disease Summit
DESCRIPTION:Following a year of exceptional progress in IBD drug development\, fierce competition in clinical trials for Chron’s Disease and Ulcerative Colitis remains high\, and it’s time for biopharma to push the boundaries of efficacy and distinguish their therapies amongst the market. \nFeaturing three days of data-driven sessions from 25+ world-class speakers\, the 3rd Precision Medicine in Inflammatory Bowel Disease returns as the field’s most comprehensive learning and networking forum; dedicated to showcasing the latest data and advances in IBD therapeutic development. \nSee the full program here: https://ter.li/tjjok6 \nWith transformative advancements in disease understanding\, AI-powered biomarker development\, patient stratification\, and advanced monitoring techniques paving the way for a new era of precision IBD therapies\, join 80+ IBD specialists to: \n\nRefine models and proof-of-concept studies to reduce clinical trial failure rates and improve translational outcomes\nInnovate treatment pathways to optimize safety and efficacy\nMinimize adverse events while enhancing therapeutic synergies\nLeverage emerging therapeutic modalities to refine patient selection and optimize therapeutic outcomes\n\nWhen & Where: May 13-15\, 2025 | Boston\, MA \nWho: 80+ Precision Medicine\, Diagnostics\, Translational\, Clinical\, Computational Biology\, Gastrointestinal and Inflammation experts \nAgenda: https://ter.li/tjjok6
URL:https://www.pharmajournalist.com/event/3rd-precision-medicine-in-inflammatory-bowel-disease-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250512
DTEND;VALUE=DATE:20250515
DTSTAMP:20260515T035145
CREATED:20250225T112204Z
LAST-MODIFIED:20250225T112204Z
UID:40566-1747008000-1747267199@www.pharmajournalist.com
SUMMARY:4th ALS Drug Development Summit
DESCRIPTION:The ALS Drug Development Summit is the definitive industry-led forum dedicated to advancing breakthroughs in ALS therapeutics. With the field evolving rapidly\, recent milestones—such as Insitro’s AI-driven target discovery with Bristol Myers Squibb and Dewpoint Therapeutics’ collaboration with Mitsubishi Tanabe Pharma America on TDP-43 condensate modulators—highlight the momentum in novel drug discovery. Meanwhile\, QurAlis’ clinical trials for QRL-101 and QRL-201 and innovations in biomarker platforms are reshaping the treatment landscape. \nJoin 200+ scientific leaders in Boston to tackle key challenges in target validation\, biomarker development\, and clinical trial optimization—driving progress toward effective ALS and FTD therapies. \nTo know more visit: https://ter.li/48rlwg
URL:https://www.pharmajournalist.com/event/4th-als-drug-development-summit/
LOCATION:Revere\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250506
DTEND;VALUE=DATE:20250509
DTSTAMP:20260515T035145
CREATED:20250220T124530Z
LAST-MODIFIED:20250220T124530Z
UID:40548-1746489600-1746748799@www.pharmajournalist.com
SUMMARY:2nd ADC Payload Summit
DESCRIPTION:The 2nd ADC Payload Summit (May 6-8 | Boston\, MA) is the first and only conference exclusively focusing on ADC payloads\, helping you to reimagine the medicinal chemistry of traditional cytotoxic payloads while scouting the next generation of ADC payload innovations. \n \nWith novel payload categories such as degraders\, RNA polymerase II inhibitors\, immunomodulators\, gene silences\, and splice modulators entering the clinic\, don’t miss this opportunity to meet with fellow peers to explore the benefits of these diverse mechanisms of action to develop the next blockbuster ADC. \nThis event will also feature cutting-edge data presentations from emerging players in the field\, including Lycia Therapeutics and Heidelberg Pharma\, showcasing their latest advancements in payload technologies and clinical trial outcomes. With 80+ professionals from across the ADC landscape in attendance\, the summit offers ample networking opportunities to foster collaboration\, exchange ideas\, and drive the future of ADC therapy forward. \nOver three days of deep discussions and collaborative sessions\, attendees will gain practical insights into optimizing payload efficacy\, improving structure-activity relationships\, and exploring the latest payload classes entering the clinic. \nHere are some of the agenda highlights you cannot afford to miss: \n– Gain insights from Eisai on “Engineering STING/TLR Agonist Payloads to Amplify Anti-Tumor Immune Responses Without Triggering Cytokine Induction” exploring the therapeutic niche and potential of STING agonist payloads. \n– Join Takeda in “Navigating the Evolution of ADC Payloads – From Topo1 Success to Future Innovation” to discuss why Topo1 inhibitors dominated the clinic so fast\, what other modes of action and payload classes need to do to match that clinical success\, and where there is whitespace for novel payloads to gain ground in a competitive ADC landscape. \n– Hear from Merck on “Accelerating Degrader-Antibody Conjugate Design Through Strategic Integration of Traditional ADC & Expertise in TPD” to learn about translating physicochemical property optimization strategies from traditional ADCs to address unique degrader payload solubility and stability challenges. \nDon’t miss this opportunity to connect with the ADC community and shape the future of payload design. Join us in Boston for this exclusive event and be at the forefront of ADC innovation. \nTo know more visit: https://ter.li/j0dvm6
URL:https://www.pharmajournalist.com/event/2nd-adc-payload-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250506
DTEND;VALUE=DATE:20250509
DTSTAMP:20260515T035145
CREATED:20250116T114600Z
LAST-MODIFIED:20250116T114600Z
UID:40301-1746489600-1746748799@www.pharmajournalist.com
SUMMARY:3rd mRNA Process Development & Manufacturing Summit Europe
DESCRIPTION:The 3rd mRNA Process Development & Manufacturing Summit 2025 returns as Europe’s premier industry-focused forum\, dedicated to optimizing process development for mRNA therapeutics and vaccines. This event will address end-to-end process optimisation\, regulatory compliance to streamline approvals\, while also advancing scalable and cost-efficient manufacturing solutions\, to support drug developers in delivering safer and more effective mRNA drugs to patients faster. \nBringing together leading experts from CEPI\, Merck\, CureVac\, BioNTech\, Altamira\, Genevation\, and more\, this summit will showcase cutting-edge advancements in end-to-end process development and manufacturing to support the production of high-quality\, cost-effective mRNA therapeutics at scale. \nDownload the event guide for full details: https://ter.li/4omn9n
URL:https://www.pharmajournalist.com/event/3rd-mrna-process-development-manufacturing-summit-europe/
LOCATION:Hotel Palace Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250429
DTEND;VALUE=DATE:20250502
DTSTAMP:20260515T035145
CREATED:20250317T140929Z
LAST-MODIFIED:20250317T140929Z
UID:40719-1745884800-1746143999@www.pharmajournalist.com
SUMMARY:2nd GLP-1-Based Therapeutics Summit
DESCRIPTION:The 2nd GLP-1-Based Therapeutics Summit is an exclusive gateway to competitive intelligence into the continued potential of cutting-edge GLP-1s for obesity\, weight loss\, diabetes\, and beyond. Join us to hear the latest clinical data on combination therapies to enhance muscle preservation\, indication expansion into new areas\, and strategies to improve the efficacy\, tolerability\, and durability of GLP-1s. With these drugs continuing to dominate the headlines\, there is no better time to unite with 100+ C-level executives\, decision-makers\, and scientists at the forefront of the rapidly evolving world of GLP-1-Based therapeutics. \nLearn more: https://ter.li/b0yt9f
URL:https://www.pharmajournalist.com/event/2nd-glp-1-based-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250429
DTEND;VALUE=DATE:20250502
DTSTAMP:20260515T035145
CREATED:20250204T091737Z
LAST-MODIFIED:20250204T091823Z
UID:40418-1745884800-1746143999@www.pharmajournalist.com
SUMMARY:2nd Measuring Patient Engagement Summit
DESCRIPTION:As the healthcare industry evolves\, patient engagement has become a crucial factor in shaping clinical trials\, accelerating regulatory approvals\, and improving the overall patient experience. \nYet\, amidst a challenging funding environment\, empowered patients rightfully demanding greater involvement in treatment decisions\, and regulatory bodies requiring transparent reporting of patient engagement activities\, it has become more critical than ever to establish quantitative measures for assessing the impact of these initiatives. \nThe 2nd Annual Measuring Patient Engagement Summit 2025 is the premier event dedicated to addressing this challenge. Bringing together top experts from Patient Engagement\, Advocacy\, Affairs\, Experience\, Insights\, and Marketing\, this summit offers a platform for thought leaders to share data-driven strategies and actionable insights. Attendees will explore innovative case studies that showcase how patient engagement initiatives can be effectively measured\, ensuring they deliver real impact while meeting compliance and ROI expectations. \nKey topics will include: \n\nEstablishing standardized metrics for patient engagement success\nAligning patient engagement strategies with regulatory expectations\nDemonstrating ROI to internal and external stakeholders\nLeveraging patient insights to improve trial design and healthcare outcomes\n\nBy uniting industry leaders to develop a consistent framework for measuring patient engagement\, this event ensures that patient-centered innovation remains at the forefront of healthcare transformation. \nJoin us to drive measurable\, meaningful progress in patient engagement — because when we quantify what matters\, we create a healthcare system that works for everyone. \nTo know more visit: www.measuring-patient-engagement-summit.com
URL:https://www.pharmajournalist.com/event/2nd-measuring-patient-engagement-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250428
DTEND;VALUE=DATE:20250501
DTSTAMP:20260515T035145
CREATED:20250116T115710Z
LAST-MODIFIED:20250116T115805Z
UID:40311-1745798400-1746057599@www.pharmajournalist.com
SUMMARY:4th ADC Analytical Development Summit
DESCRIPTION:Unlock the Future of ADC Analytics at the 4th ADC Analytical Development Summit! \nWhen: April 2025\nWhere: Boston \nThe 4th ADC Analytical Development Summit is back\, bringing together top minds and innovators to tackle the unique analytical challenges of antibody-drug conjugates. With ADCs becoming more complex and regulatory requirements tightening\, this event will be your ultimate guide to mastering strategies that ensure high-quality products and seamless regulatory submissions. \nView the program here: https://ter.li/hi4hm1 \n\nWhy You Can’t Miss This Summit: \n3 Days of Cutting-Edge Scientific Content \nExplore sessions that cover critical topics\, including: \n\nOptimizing DAR quantification\nImproving aggregation analysis\nRefining impurity profiling for advanced ADC development\n\n25+ Expert Speakers \nLearn from top industry leaders and innovators\, featuring experts from: \n\nAstraZeneca\nAbbVie\nSutro Biopharma\nMerck\n…and many more!\n\n6+ Hours of Interactive Workshops \nParticipate in hands-on workshops to dive deeper into: \n\nStrategies for accelerated approvals\nAdvanced profiling techniques for product characterization\nPotency optimization for improved therapeutic outcomes\nCrafting data packages for smooth regulatory submissions\n\n5+ Hours of High-Impact Networking \nConnect with over 120 analytical scientists and quality control specialists to build valuable collaborations and share expertise. \nFind out more here: https://ter.li/hi4hm1
URL:https://www.pharmajournalist.com/event/4th-adc-analytical-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250422
DTEND;VALUE=DATE:20250425
DTSTAMP:20260515T035145
CREATED:20241128T082522Z
LAST-MODIFIED:20241128T082522Z
UID:40196-1745280000-1745539199@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences West
DESCRIPTION:LEAP HR: Life Sciences West is your chance to explore how leading and emerging biopharma organizations are navigating industry volatility and preparing for the workforce of tomorrow. As the sector recovers from funding challenges and workforce reductions\, discover innovative ways to align your HR strategy with evolving business needs in 2025 and beyond. \nJoin 200+ HR leaders to uncover how the most agile organizations are reshaping total rewards strategies to gain a competitive edge in a fiercely competitive talent market. Learn how they’re redefining employee engagement to boost retention and creating flexible workforce planning strategies to adapt to rapid industry changes. \nThis is your opportunity to rethink HR practices and position your organization for long-term success in Life Sciences. \nTo know more visit: https://ter.li/fxwk88
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-west/
LOCATION:Grand Hyatt San Francisco\, 345 Stockton St\, San Francisco\, CA\, 94108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250409
DTEND;VALUE=DATE:20250411
DTSTAMP:20260515T035145
CREATED:20250228T122457Z
LAST-MODIFIED:20250228T122457Z
UID:40603-1744156800-1744329599@www.pharmajournalist.com
SUMMARY:Tumour Models Summit Nordics
DESCRIPTION:Welcome to the first ever Tumour Models Summit Nordics. This April\, the critically acclaimed Tumour Models series will be coming to the Nordics for the first time ever\, uniting more than seventy pharma\, biotech\, and research leaders across the Nordic biotech landscape. \nThe inherent heterogeneity of cancer – both inter-patient and intra-tumoral – remains a significant challenge in cancer modelling. With only 5% of cancer drugs successfully advancing to clinical trials\, there is a critical need for more accurate and predictive models to guide therapeutic development. \nTo serve this need\, the Tumour Models Summit Nordics will unite pharma\, biotech\, and research leaders from across the thriving Nordic biotech ecosystem to tackle this challenge head-on for the first time ever. Experts working across preclinical\, translational\, discovery\, toxicity\, and biology will gather in Stockholm this April to collaborate and overcome the industry’s biggest obstacles for 2025. As the region’s only industry-led event of its kind\, this summit provides a rare opportunity to connect with top experts from these developmental areas. \nGain insights into the cutting-edge innovation in in vivo and in vitro tumour modelling\, discover strategies to de-risk your studies\, and learn how to refine your drug development pipeline. \nKey highlights of the agenda include: \n\nLeveraging cutting-edge 3D in vitro models with Roche\nTarget/receptor axis modelling with Anocca\nHumanised mouse models with BioInvent\nAdvanced omics data with Curacell\nTreating solid tumours with Hemispherian\n\nPrevious attendees of the Tumour Models Summits in Boston\, San Francisco\, and London have celebrated the summit’s range\, relevance\, and focus with comments such as\, “This summit included the most cutting-edge achievements and potential collaborations in the scientific and industrial world” (Roche)\, and “The conference exceeded my expectations. The talks were very relevant to my day-to-day work as in vivo scientist in a cell therapy company. I enjoyed the networking; attendees were very approachable” (Arsenal Biosciences). \nFind out why they said this and secure your free pass to join us to engage with decision-makers\, explore groundbreaking solutions\, and accelerate the path from lab to patient in today’s rapidly evolving landscape. \nWe’ll see you there! \nGet your free pass now whilst still available: https://ter.li/qdc9zo
URL:https://www.pharmajournalist.com/event/tumour-models-summit-nordics/
LOCATION:Hilton Stockholm Slussen\, Guldgränd 8\, Stockholm\, 104 65\, Sweden
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250408
DTEND;VALUE=DATE:20250411
DTSTAMP:20260515T035145
CREATED:20250214T121248Z
LAST-MODIFIED:20250214T121248Z
UID:40497-1744070400-1744329599@www.pharmajournalist.com
SUMMARY:15th World Clinical Biomarkers & Companion Diagnostics Summit Europe
DESCRIPTION:As recent advances in small molecules\, ADCs\, cell\, and gene therapies poise novel precision therapies from the bench to the clinic\, the 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe returns as the industry-leading end-to-end forum for Europe’s precision medicine community. \nOver three days\, 170+ key stakeholders from across Europe working in Biomarkers\, Translational Medicine\, Precision Medicine\, and Companion Diagnostics will come together to: \n\nBolster biomarker discovery and validation\nImplement novel technologies and trials\nPioneer digital and AI-enabled innovations\nOptimise drug-diagnostic co-development\nStreamline CDx development and commercialisation\nNavigate IVDR-adherence\n\nWhen? 8th-10th April\, 2025 \nWhere? London\, UK \nSee the brochure: https://ter.li/exx85v \nWith free* tickets available for biopharma\, check our T&Cs\, or view our early bird savings and group discounts: https://ter.li/5uhfl8
URL:https://www.pharmajournalist.com/event/15th-world-clinical-biomarkers-companion-diagnostics-summit-europe/
LOCATION:London\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250401
DTEND;VALUE=DATE:20250404
DTSTAMP:20260515T035145
CREATED:20250127T201431Z
LAST-MODIFIED:20250127T201431Z
UID:40370-1743465600-1743724799@www.pharmajournalist.com
SUMMARY:6th TCR-Based Therapies Summit
DESCRIPTION:Returning as the only event created selectively for and by the TCR community\, the 6th TCR-based Therapies Summit (April 1-3\, 2025 | Boston\, MA) is your unique opportunity to connect and collaborate with TCR developers and experts to battle the specific discovery\, preclinical and clinical challenges created by T cell receptor biology to advance cell- and bispecific approaches. \nView the 25+ experts speaking in 2025 including Adaptimmune\, Immunocore\, Immatics\, BioNTech\, T-Knife\, TScan\, and Affini-T Therapeutics. \nView the full lineup of presenting companies in the 2025 Event Guide. \nReturning as a much-loved forum by industry leaders in this close-knit community\, I’m sure you want to know what’s new for the 2025 meeting: \n\nPlethora of new data: Over 60% of talks will share new data\, including clinical insights and advances\, novel target case studies\, and innovations utilizing AI\, machine learning\, engineering methods\, and cell tracking\nBreadth of TCR Approaches: Uncover the realm of TCR targeting methods including TCR-Ts\, TCR-NKs\, bispecifics\, T-cell engagers\, TCR-like antibodies\, and mimics\, and distinguishing the optimal approach for different indications\n7 New Companies & 85% New Speakers: Unlock innovations from companies such as Moonlight Bio\, Synteny\, Alkemist Bio\, Pan Cancer T\, and Aethon Therapeutics making their TCR-Based Therapies Summit debut and hear new perspectives from a highly refreshed speaker faculty\nApplications Beyond Oncology: Discover how TCR therapies can be utilized to treat novel indications\, such as autoimmunity and infectious diseases\, and harness cross-learnings to propel your therapeutic development\n\nView the full program. \nFollowing Adaptimmune’s milestone approval\, the 2025 meeting is anticipated to be one of the best yet. With so much to celebrate\, momentum to capture\, novel insights\, and collaboration with like-minded experts at the only TCR-specific event. \nQuick links: Website | Event Guide | Register
URL:https://www.pharmajournalist.com/event/6th-tcr-based-therapies-summit/
LOCATION:The Revere Hotel Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250401
DTEND;VALUE=DATE:20250404
DTSTAMP:20260515T035145
CREATED:20241204T190232Z
LAST-MODIFIED:20241204T190232Z
UID:40220-1743465600-1743724799@www.pharmajournalist.com
SUMMARY:2nd Peptide-Based Therapeutics Summit
DESCRIPTION:The 2nd Peptide-Based Therapeutics Summit will return to Boston in April 2025\, bringing together over 80 experts in peptide computational science\, medicinal chemistry\, and formulation to discuss the latest advancements shaping the next generation of peptide-based therapies—from early-stage discovery to clinical application. \nDownload the three-day program here: https://ter.li/rrvg1v \nThis year’s summit will highlight groundbreaking innovations in peptide therapeutics\, including: \n\nPeptide 3D structure prediction\, hit generation\, and lead optimization\, featuring insights from Chugai Pharmaceutical\, PeptiDream\, and Insamo\nStrategies for optimizing oral bioavailability and cell permeability in peptide design\, with contributions from Orbis Medicines and Ohio State University\nPeptide formulation techniques for optimal target binding\, solubility\, stability\, and safety\, with expertise from Halozyme and Oramed Pharmaceuticals\n\nJoin us to shape your peptide drug discovery and development strategy for 2025 and discover the therapeutic potential of cutting-edge peptide-based medicines.
URL:https://www.pharmajournalist.com/event/2nd-peptide-based-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250401
DTEND;VALUE=DATE:20250404
DTSTAMP:20260515T035145
CREATED:20241127T123831Z
LAST-MODIFIED:20241127T123902Z
UID:40151-1743465600-1743724799@www.pharmajournalist.com
SUMMARY:Nasal Formulation & Delivery Summit
DESCRIPTION:With nasal delivery systems offering faster absorption and non-invasive administration\, they are becoming a cornerstone of modern therapeutics. Whether for nose-to-brain delivery or emergency use\, nasal delivery is opening a new era of more efficient drug and vaccine administration with life-saving potential. However\, challenges in biologics formulation\, along with renewed interest from major pharmaceutical companies and investors\, raise questions about how other companies are addressing development obstacles and the most effective strategies to secure funding. \nDedicated to navigating investment pathways for nasal companies\, boosting drug bioavailability in target regions\, optimizing translational modelling\, and determining the efficacy of delivery devices\, the 3rd Nasal Formulation & Delivery Summit will unite biotechs and innovative start-ups to share case studies and best practices in optimizing nasal drug delivery across different therapeutic areas. \nDownload the event guide for full details: https://ter.li/qd1z5z \nEarly bird savings and group discounts up to 20% are available\, check out the options here: https://ter.li/u7ehtp
URL:https://www.pharmajournalist.com/event/nasal-formulation-delivery-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR